Performance evaluation of NeuMoDx 96, a random access system for CMV DNA quantitation

Area of Science:

• Virology
• Clinical Diagnostics
• Molecular Biology

Background:

• Cytomegalovirus (CMV) infection is a major threat to immunocompromised individuals, especially after transplantation.
• Early and precise quantification of CMV DNA is critical for effective patient management and preventing severe outcomes.
• Current diagnostic methods, often batch-based, may not offer the rapid turnaround needed for critically ill patients.

Purpose of the Study:

• To evaluate the diagnostic performance of the NeuMoDx 96 random-access CMV assay.
• To compare the NeuMoDx 96 assay against the established COBAS® AmpliPrep/COBAS® TaqMan® CMV assay.
• To assess the NeuMoDx 96 assay's concordance with the World Health Organization (WHO) International Standard for CMV.

Main Methods:

• Retrospective analysis of 104 archived plasma samples.
• Comparison of the NeuMoDx 96 CMV assay with the COBAS® AmpliPrep/COBAS® TaqMan® CMV assay.
• Quantification using the WHO International Standard for CMV for calibration and validation.

Main Results:

• The NeuMoDx 96 assay demonstrated high diagnostic accuracy, with 98.2% sensitivity and 100% specificity compared to the COBAS® assay.
• Excellent concordance was observed between the NeuMoDx 96 assay results and the WHO International Standard for CMV.
• The NeuMoDx 96 platform offers a rapid and potentially cost-effective alternative for CMV DNA quantification.

Conclusions:

• The NeuMoDx 96 platform is a reliable and accurate tool for CMV DNA detection in clinical settings.
• This random-access assay can facilitate faster clinical decision-making for managing CMV infections in vulnerable patient populations.
• Further validation across diverse clinical environments is recommended to broaden the application of this rapid diagnostic technology.